Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. scores highest on Torque (65) and lowest on Nitro (27). Its PosiPenta is 43.88 out of 100, around the middle of similar companies.
On the Penta Grid this week, Fulcrum Therapeutics, Inc. is Grid #413 of 837 in the Healthcare sector in United States, and Grid #2,517 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | 43.88 | 40 | 52 | 27 | 65 | 35 |
| InfuSystem Holdings, Inc. | 58.99 | 33 | 61 | 95 | 60 | 45 |
| ClearPoint Neuro, Inc. | 23.73 | 2 | 34 | 28 | 9 | 46 |
| Anika Therapeutics, Inc. | 64.30 | 29 | 83 | 89 | 59 | 61 |
| Vogenx, Inc. | 48.79 | 0 | 70 | 33 | 95 | 45 |
| Treace Medical Concepts, Inc. | 39.41 | 17 | 39 | 61 | 28 | 52 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.02 |
| P/B ratio | 0.90 |
EEarnings
| Trailing EPS | ₹-114.61 |
| Forward EPS | ₹-51.86 |
NNitro
| Price | 345.71 |
| 52-week high | 1490.81 |
| 52-week low | 268.04 |
| Fall from 52-week high | 76.8% |
TTorque
| Return on equity (ROE) | -32.38% |
| Debt-to-equity | 0.02 |
AAnchor
| Beta (price swings) | 2.63 |
| Market cap | ₹2,640 Cr |
| Insider holding | 3.35% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Fulcrum Therapeutics, Inc.'s PosiPenta score?
Fulcrum Therapeutics, Inc.'s PosiPenta is 43.88 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Fulcrum Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Fulcrum Therapeutics, Inc. is Grid #413 of 837 in the Healthcare sector in United States, and Grid #2,517 of 4,000 in United States.
Which PosiPenta pillar is strongest for Fulcrum Therapeutics, Inc.?
Torque (durability), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Fulcrum Therapeutics, Inc.?
Nitro (momentum), with a score of 27 out of 100: weaker than most similar companies.
Has Fulcrum Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.50 points, from 40.38 to 43.88.
PositoAI is for research and education only and is not investment advice.